The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies

RECOMMENDED

Asthma

Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial

Lancet Respir Med.

Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Sproule S, Olsson RF, Martin UJ, Goldman M; BORA study investigators

doi: 10.1016/S2213-2600

Asthma

Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies

Lancet Respir Med.

FitzGerald JM, Bleecker ER, Menzies-Gow A, Zangrilli JG, Hirsch I, Metcalfe P, Newbold P, Goldman M

doi: 10.1016/

Asthma

Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial

Lancet.

Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkström V, Goldman M; SIROCCO study investigators

doi: 10.1016/

Asthma

Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma

Ann Allergy Asthma Immunol.

Chipps BE, Newbold P, Hirsch I, Trudo F, Goldman M

doi: 10.1016/j.anai.2018.01.030.

Asthma

Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma

Adv Ther.

Jackson DJ, Humbert M, Hirsch I, Newbold P, Garcia Gil E

doi: 10.1007/s12325-019-01191-2.

RECOMMENDED

Asthma

Relationship Between Benralizumab Exposure and Efficacy for Patients with Severe Eosinophilic Asthma

Clin Pharmacol Ther.

Chia YL, Yan L, Yu B, Wang B, Barker P, Goldman M, Roskos L

doi: 10.1002/cpt.

Asthma

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

Lancet.

FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Busse WW, Barker P, Sproule S, Gilmartin G, Werkström V, Aurivillius M, Goldman M; CALIMA study investigators

doi: 10.1016/

RECOMMENDED

Asthma

Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma

Eur Respir J.

Bleecker ER, Wechsler ME, FitzGerald JM, Menzies-Gow A, Wu Y, Hirsch I, Goldman M, Newbold P, Zangrilli JG

doi: 10.1183/13993003.

RECOMMENDED

Asthma

Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison

J Allergy Clin Immunol.

Busse W, Chupp G, Nagase H, Albers FC, Doyle S, Shen Q, Bratton DJ, Gunsoy NB

doi: 10.1016/j.jaci.2018.08.031.

Related content

Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial

Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies

Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial

Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma

Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma

Relationship Between Benralizumab Exposure and Efficacy for Patients with Severe Eosinophilic Asthma

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma

Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison